These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6430322)

  • 41. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate.
    Young J; Hall P; Blakemore C
    Br J Psychiatry; 1974 Feb; 124(579):177-80. PubMed ID: 4596673
    [No Abstract]   [Full Text] [Related]  

  • 42. Cyclandelate in long standing cerebral arteriosclerosis.
    Rogers WF; Shaikh VA; Clark AN
    Gerontol Clin (Basel); 1970; 12(2):88-93. PubMed ID: 4987660
    [No Abstract]   [Full Text] [Related]  

  • 43. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
    Fine EW; Lewis D; Villa-Landa I; Blakemore CB
    Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174
    [No Abstract]   [Full Text] [Related]  

  • 44. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 45. The effect of cyclandelate on cholesterol synthesis.
    Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
    Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
    [No Abstract]   [Full Text] [Related]  

  • 46. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 47. [Use of Polydes in patients with atherosclerosis of the abdominal aorta].
    Matveeva AI; Shcherbinina SP
    Khirurgiia (Mosk); 1979 Jan; (1):97-100. PubMed ID: 759712
    [No Abstract]   [Full Text] [Related]  

  • 48. High-performance liquid chromatographic method for the determination of a cyclandelate metabolite, mandelic acid, in human plasma.
    Kojima K; Uezono Y; Takahashi T; Nakanishi Y
    J Chromatogr; 1988 Mar; 425(1):203-7. PubMed ID: 3360871
    [No Abstract]   [Full Text] [Related]  

  • 49. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography.
    Andermann G; Dietz M
    J Chromatogr; 1981 May; 223(2):365-70. PubMed ID: 7251791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preliminary study of the effects of cyclandelate.
    Davies G
    Med J Aust; 1971 Feb; 1(6):313-7. PubMed ID: 4925923
    [No Abstract]   [Full Text] [Related]  

  • 51. Electroencephalographic study of dose-response relations for cyclandelate on hyperventilation-induced vasospasm in human brain.
    Korenyi C; Whittier JR
    Angiology; 1969 Oct; 20(9):529-34. PubMed ID: 5824354
    [No Abstract]   [Full Text] [Related]  

  • 52. Retardation of experimental atherosclerosis in endarterectomized arteries by the administration of heparin and dextran.
    Pilcher DB; Barker WF
    Am J Surg; 1970 Aug; 120(2):270-4. PubMed ID: 5456416
    [No Abstract]   [Full Text] [Related]  

  • 53. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 54. Investigation on spasmolytics. VII. The metabolism of 3,5,5-trimethylcyclohexylmandelate (cyclandelate). II.
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jun; 12():632-5. PubMed ID: 13890671
    [No Abstract]   [Full Text] [Related]  

  • 55. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

  • 56. The treatment of peripheral vascular diseases with cyclospasmol (mandelic acid ester of 3, 5, 5-trimethylcyclohexanol).
    VAN WIJK TW
    Angiology; 1953 Apr; 4(2):103-13. PubMed ID: 13040814
    [No Abstract]   [Full Text] [Related]  

  • 57. Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas.
    Wissler RW; Vesselinovitch D
    Appl Pathol; 1983; 1(2):89-96. PubMed ID: 6678159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cyclospasmol (mandelic acid ester of 3,5,5-trimethylcyclohexanol) in therapy of skin diseases].
    DOORNINK FJ
    Geneeskd Gids; 1953 Jun; 31(12):247-51. PubMed ID: 13083900
    [No Abstract]   [Full Text] [Related]  

  • 59. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective action of cyclandelate in hypoxia.
    Funcke AB; van Beek MC; Nijland K
    Curr Med Res Opin; 1974; 2(1):37-42. PubMed ID: 4842317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.